Newsletter · · Ashutosh Agarwal

Lilly's Retatrutide Shows 28% Weight Loss and Novo Cuts Wegovy List Price by Half - The GLP-1 Complex - Week of May 25–28, 2026

GLP-1 complex newsletter for the week of May 25–28, 2026. Lilly's retatrutide top-line pulls bariatric surgery into a price fight while Novo's CEO concedes the branded list-price ceiling ahead of ADA.

The GLP-1 Complex

Week of May 25–28, 2026: Lilly's Retatrutide Shows 28% Weight Loss and Novo Cuts Wegovy List Price by Half

Two things happened in the last seven days that real money should care about. Eli Lilly's retatrutide put up a number that pulls bariatric surgery's pricing moat into a knife fight, and Novo's CEO walked onto The Journal and quietly conceded the list-price ceiling on branded GLP-1s. Everything else this week is a footnote to those two, but a couple of the footnotes are worth your morning coffee, so let's get into it.

TL;DR

  • Retatrutide TRIUMP-1 top-line landed: 28.3% body weight loss at 80 weeks, 45.3% of patients hit the >30% weight-loss bar that historically belonged to surgery, and discontinuations came in below placebo. Full data hits ADA in early June.
  • Novo capitulated on list price. Wegovy goes to $675/mo in 2027, a 50% list cut; Ozempic down about 35%. CEO Mike Doustdar called the list-to-net spread "out of whack." The net-price story is now the only story.
  • Real-world persistence climbed from 33% to 61% over the last five years, and the anti-inflammatory read on osteoarthritis is getting louder, both quietly bullish for chronic-therapy revenue and quietly bearish for ortho volumes.

🆕 What's new

Retatrutide just made bariatric surgeons nervous. On Diabetes Dialogue's pre-ADA episode, endocrine specialist Natalie Bellini walked through Lilly's TRIUMP-1 top-line: 70.3 lbs, 28.3% body weight, 45.3% of patients >30%, "where bariatric surgery plays a role." The 104-week extension in the higher-BMI cohort hit 30.3% and had not plateaued. The kicker: "The discontinuation rate, ready for this, is lower than placebo." If that holds in the full read-out at ADA, retatrutide isn't just a more powerful drug, it's a more tolerable one, which is the part of the model the Street still underwrites conservatively.

"45.3% of participants hit greater than or equal to 30% weight loss, which is where bariatric surgery plays a role.", Natalie Bellini, Diabetes Dialogue, May 28

Novo's CEO told you the price war is real. On The Journal, Mike Doustdar confirmed Novo is dropping US list to $675/month in 2027, half off Wegovy, a third off Ozempic. He framed it as cleaning up a "list-to-net out of whack," which is CEO-speak for we were already there on rebate; we're just rationalizing optics. Read it that way and you should be tightening your gross-to-net assumptions, not your topline. He also disclosed oral Wegovy is doing >1.3M scripts in Q1 with 80% of pickups being new patients: that's not cannibalization, that's a needle-averse cohort finally entering the funnel.

SURMOUNT-MAINTAIN says the chronic-therapy thesis has teeth. On Docs Who Lift, Spencer and Karl Nadolsky walked through the dose-de-escalation data: of patients who hit about 22% weight loss on max-dose tirzepatide, only 8% needed rescue therapy if they stayed on max vs. 25% who down-titrated to 5mg and 67% who went to placebo. Translation: this is a chronic drug, period. Worth flagging that Karl Nadolsky disclosed on-air he's a "paid speaker for Lilly on orforglipron," so discount his orforglipron commentary accordingly.

Orforglipron pricing matters more than orforglipron data. Same Docs Who Lift episode: ATTAIN-MAINTAIN data showed patients switching from tirzepatide to orforglipron held about 75% of weight loss; the sema-to-orfo switch held about 80%. Standalone, orfo lands at about 11% weight loss, clearly second-tier on efficacy. But here's the spicy bit from Spencer Nadolsky:

"I could totally see [insurers mandating a switch to orforglipron] because of these trials… from a direct-to-consumer cost perspective."

A treating physician anticipating PBM step-therapy onto the cheaper oral. That's exactly what gross-to-net compression looks like before it shows up in a Lilly 10-Q.

Persistence has nearly doubled. Dr. Paul Kolodzik on The Second Opinion Podcast cited 12-month persistence rising from about 33% in 2021 to about 61% today, attributing the move largely to out-of-pocket cost coming down. He didn't cite a study, so anchor to it with a grain of salt, but it directionally aligns with what payers are seeing.

⚖️ The debate

Bull case (loud on the tape this week): 28% weight loss at retatrutide doses with discontinuations below placebo, 45% hitting bariatric-grade weight loss, persistence climbing past 60%, oral Wegovy pulling in needle-averse new patients at 1.3M scripts in a single quarter. The TAM compounds; the medical pool keeps growing; durable chronic dosing is materializing in real-world data.

Bear case (subtler, but in the same tapes): A 50% list cut isn't a victory lap, it's a ceiling. Doustdar himself flagged that e-health/DTC is the fastest-growing channel for both Novo and Lilly, a margin-dilutive mix shift dressed up as growth. Novo's pipeline answer is a Chinese-sourced triple agonist (UBT-251), which is the CEO talking his book at Phase 2. And the same physicians who like the drugs are openly anticipating PBM step-therapy onto cheaper oral GLP-1s.

The fast-followers worth pricing into a bear case, Amgen MariTide, Viking, Structure, Roche petrelintide, were silent on the investor podcasts this week. With ADA the following week, that silence likely doesn't last.

🎯 The names in play

LLY: Bull. The retatrutide top-line is the cleanest tape we've had on the name in months. Next catalyst is the full data drop at ADA in early June, then TRIUMP-2 (T2D) and TRIUMP-3 (CVD) in H2 2026. Watch the tolerability print at full data; if discontinuation truly tracks below placebo, the Street is still under-modeling persistence.

NVO: Mixed. The pricing reset clears uncertainty but caps the upside. Oral Wegovy traction is real and the 80% new-patient mix is a structural positive. But Doustdar volunteering UBT-251 as a retatrutide answer in Phase 2 is exactly the kind of CEO commentary you fade.

DXCM: Material new headline. On Diabetes Dialogue, Diana Isaacs and Bellini disclosed that two scrapped DexCom sensor lots, pulled pre-sterilization for quality failure, were stolen from trucks and resold by third parties. That's a sterility-risk patient-safety event with reputational tail risk. Layer it on Abbott's CE mark for Libre Duo (dual glucose/ketone, 15-day) and the competitive setup just got worse. This deserves a phone call to IR.

SYK / ZBH: Quiet bearish. Kolodzik flagged osteoarthritis pain relief on GLP-1s beyond what weight loss alone explains, attributing it to the anti-inflammatory mechanism. If that read holds in published data, the structural knee/hip surgical pool shrinks, not just delays.

🔁 Read-throughs

Bariatric / ISRG: Bellini explicitly said retatrutide's 45% >30%-weight-loss rate is "getting close to the bariatric surgery data," and Isaacs corroborated that patients are actively delaying surgical referrals to wait for retatrutide. The bariatric volume hit moves from "potential" to "happening."

Sleep apnea (RMD/INSP), cardiac monitoring (IRTC), packaged food (PEP/MDLZ/GIS/HSY), pen-device suppliers (WST, Stevanato), Catalent fill-finish: Not voiced on the investor podcasts this week. Worth noting the staples read-through gap given how loud that debate has been in prior weeks, likely waiting for the next round of grocer scanner data.

🔀 What changed

The price-ceiling debate is effectively settled. Novo's $675 list isn't a hypothetical; it's a 2027 reality, and Lilly's response is now the question, not whether one is coming. Combine that with retatrutide's tolerability print and persistence climbing into the 60s, and the model you're running on branded GLP-1s should look less like a luxury good and more like a chronic specialty drug with secular volume tailwinds and a flat-to-down price curve. That's a different multiple.

The fast-follower silence is conspicuous. ADA week is going to be loud.

Sources